How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to the consensus estimate of $15.65 million.

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX) , Immunomedics (IMMU) , Progenics Pharmaceuticals (PGNX) , Inovio Pharmaceuticals (INO) , ACADIA Pharmaceuticals (ACAD) , Cara Therapeutics (CARA) , OPKO Health (OPK) , Gilead Sciences (GILD) , Exelixis (EXEL) and

NASDAQ:SGYP

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Free SGYP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.01
▼
$0.03
52-Week Range: N/A

Volume: N/A
Average Volume: 6.08 million shs
Market Capitalization: $7.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Synergy Pharmaceuticals alerts:

Ad Weiss Ratings

The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Ad Weiss Ratings

The only accurate crypto trading system I know …

Here's what our expert says you should buy before April 14.

SGYP Stock News Headlines

April 12, 2024 | seekingalpha.com

Jose Solorio

January 2, 2024 | msn.com

PYC Therapeutics and Google Cloud partner for new precision medicines

April 16, 2024 | Weiss Ratings (Ad)

The only accurate crypto trading system I know …

May 9, 2023 | investing.com

Synergy Pharmaceuticals Inc Unit (SGYPU)

April 12, 2023 | forbes.com

Market Factor Synergy Signals Exciting Growth For Digital Pathology

March 29, 2023 | bbc.co.uk

Different resistors

March 28, 2023 | bbc.co.uk

Mains cables

March 28, 2023 | bbc.co.uk

Energy changes in braking

April 16, 2024 | Weiss Ratings (Ad)

The only accurate crypto trading system I know …

December 18, 2022 | thestreet.com

Synergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson Investment

September 13, 2022 | investing.com

Jiangxi Synergy Pharmaceutical Co Ltd (300636)

May 16, 2022 | seekingalpha.com

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript

January 18, 2022 | thestreet.com

Here's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Today

December 2, 2021 | finanznachrichten.de

OKYO Pharma LTD: OKYO Pharma Limited: Directorate Change

See More Headlines

Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2018
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:SGYP
CUSIP: 87163930
CIK: 1347613
Web: www.synergypharma.com
Phone: 212-297-0020
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-224,330,000.00
Net Margins: -332.11%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -118.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.52
Quick Ratio: 0.38

Sales & Book Value

Annual Sales: $16.82 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 248,040,000
Free Float: N/A
Market Cap: $7.44 million
Optionable: Optionable
Beta: 4.94

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Troy Hamilton Pharm.D. (Age 47)
CEO & Director
Mr. Gary G. Gemignani (Age 54)
Exec. VP & CFO
Gem Gokmen Hopkins
VP of Investor Relations and Corp. Communications
Ms. Pamela Cebulski
Sr. VP of Marketing
Ms. Marianne Jackson
Sr. VP of Sales & Market Access

Key Competitors

View All Competitors

SGYP Stock Analysis - Frequently Asked Questions

How were Synergy Pharmaceuticals' earnings last quarter?: Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to the consensus estimate of $15.65 million.
What other stocks do shareholders of Synergy Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and

This page (NASDAQ:SGYP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

SGYP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

SGYP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info